Physician profile
Mark Wheeler
NPI 1215985551
$3,502.72
in general payments reported to CMS, 2019-2025
30 companies · $532 in 2025
The $532 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $296 · 2021: $411 · 2022: $532 · 2023: $754 · 2024: $522 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.49 | 2021-2025 | Dalvance, Teflaro, Avycaz |
| Pfizer INC. | $465.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $313.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $308.05 | 2019-2024 | Xarelto |
| Amgen INC. | $213.68 | 2019-2024 | Repatha |
| Mylan Specialty L.P. | $141.55 | 2019-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $135.29 | 2021-2023 | Camzyos |
| Allergan, INC. | $123.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $121.96 | 2020-2025 | Verquvo, Zerbaxa |
| Gilead Sciences, INC. | $101.29 | 2022-2023 | Veklury |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.43 | 2024-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $67.39 | 2020-2024 | Andexxa, Farxiga |
| Alexion Pharmaceuticals, INC. | $67.37 | 2022-2023 | Ultomiris, Soliris |
| Mallinckrodt Hospital Products INC. | $55.51 | 2024-2025 | Terlivaz |
| Shionogi INC | $50.13 | 2024 | Fetroja |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $46.94 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $44.05 | 2025 | |
| Smith+Nephew, INC. | $33.20 | 2023 | Collagenase Santyl |
| Cvrx, INC. | $31.73 | 2025 | Barostim Neo System |
| Viatris Specialty LLC | $30.30 | 2025 | Yupelri |
| Insmed, INC. | $29.97 | 2021 | |
| Inari Medical, INC. | $29.71 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bayer Healthcare Pharmaceuticals INC. | $28.70 | 2022 | |
| Abiomed | $24.41 | 2024 | Impella |
| Chiesi USA, INC. | $19.76 | 2024 | Cleviprex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.02 | 2019 | |
| Global Blood Therapeutics, INC. | $17.81 | 2021 | |
| Lilly USA, LLC | $16.30 | 2020 | |
| Novo Nordisk INC | $14.95 | 2025 | |
| Portola Pharmaceuticals, LLC | $14.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.